Budesonide
- Generic Name
- Budesonide
- Brand Names
- Airsupra, Breyna, Breztri, Cortiment, Entocort, Pulmicort, Pulmicort Turbuhaler, Rhinocort, Symbicort, Tarpeyo, Uceris, Jorveza, Kinpeygo
- Drug Type
- Small Molecule
- Chemical Formula
- C25H34O6
- CAS Number
- 51333-22-3
- Unique Ingredient Identifier
- Q3OKS62Q6X
- Background
Budesonide is a glucocorticoid that is a mix of the 22R and 22S epimer used to treat inflammatory conditions of the lungs and intestines such as asthma, COPD, Crohn's disease, and ulcerative colitis.
Budesonide was granted FDA approval on 14 February 1994. It is also available in a combination product with formoterol.
- Indication
Budesonide extended release capsules are indicated for the treatment and maintenance of mild to moderate Crohn’s disease. Various inhaled budesonide products are indicated for prophylactic therapy in asthma and to reduce exacerbations of COPD. A budesonide nasal spray is available over the counter for symptoms of hay fever and upper respiratory allergies. Extended-release capsules are indicated to induce remission of mild to moderate ulcerative colitis and a rectal foam is used for mild to moderate distal ulcerative colitis. In addition, a delayed-release capsule formulation of budesonide is indicated to reduce proteinuria in adults with IgA nephropathy at risk of rapid disease progression. In Europe, budesonide is indicated to treat eosinophilic esophagitis (EoE) in adults.
- Associated Conditions
- Allergic Reaction, Allergic Rhinitis (AR), Asthma, Bronchoconstriction, Chronic Obstructive Pulmonary Disease (COPD), Collagenous Colitis, Crohn's Disease (CD), Eosinophilic Esophagitis, Exacerbation of asthma, Nasal Congestion, Nasal Polyps, Proteinuria, Pruritus, Rhino Sinusitis, Ulcerative Colitis, Vasomotor Rhinitis, Corticosteroid-responsive dermatoses, Mild Crohn’s Disease, Moderate Crohn’s Disease
- Associated Therapies
- Maintenance therapy
Once Daily Versus Twice Daily Budesonide Orodispersible Tablets for Induction of Remission in EoE
- First Posted Date
- 2024-09-19
- Last Posted Date
- 2025-04-23
- Lead Sponsor
- Dr. Falk Pharma GmbH
- Target Recruit Count
- 308
- Registration Number
- NCT06596252
- Locations
- 🇺🇸
Dr. Falk Investigational Site, Harlingen, Texas, United States
🇪🇸Department of Gastroenterology, Hospital General de Tomelloso, Tomelloso, Spain
Bioequivalence of IMP 08P1707F0 Relative to Pulmicort® (1.0 Mg/2 Ml Suspension)
- First Posted Date
- 2024-09-19
- Last Posted Date
- 2024-11-08
- Lead Sponsor
- Unither Pharmaceuticals, France
- Target Recruit Count
- 24
- Registration Number
- NCT06595121
- Locations
- 🇹🇷
Farmagen IKU Merkezi, Gaziantep, Turkey
Replication of the NefIgArd Trial of TRF-budesonide in Primary IgAN
- Conditions
- Primary IgA Nephropathy
- Interventions
- First Posted Date
- 2024-09-10
- Last Posted Date
- 2024-09-10
- Lead Sponsor
- Ruijin Hospital
- Target Recruit Count
- 200
- Registration Number
- NCT06589752
- Locations
- 🇨🇳
Ruijin hospital, Shanghai, China
Effect of the Inhaled Triple Therapies Over the Small Airway in Biomass Exposure
- Conditions
- COPD BronchitisPollution Related Respiratory Disorder
- Interventions
- Drug: Beclomethasone / Formoterol / Glycopyrronyum 100/6/12.5 mcg
- First Posted Date
- 2024-08-26
- Last Posted Date
- 2024-08-26
- Target Recruit Count
- 128
- Registration Number
- NCT06571942
- Locations
- 🇲🇽
Insituto Nacional de Enfermedades Respiratorias "Ismael Cosío Villegas", Ciudad de México, Tlalpan, Mexico
Exacerbations Among Patients Receiving Breztri (EROS Study)
- First Posted Date
- 2024-07-23
- Last Posted Date
- 2024-12-13
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 2409
- Registration Number
- NCT06514144
- Locations
- 🇺🇸
AstraZeneca, Wilmington, Delaware, United States
Chronicling the COPD Patient Journey and Change in COPD Symptoms, Quality of Life and Exacerbations Following Initiation of Budenoside/Glycopyrronium/Formoterol [BGF]
- Conditions
- Chronic Obstructive Pulmonary Disease (COPD)
- Interventions
- First Posted Date
- 2024-07-19
- Last Posted Date
- 2025-05-13
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 200
- Registration Number
- NCT06511193
- Locations
- 🇨🇦
Research Site, Windsor, Ontario, Canada
Change in Patient-repOrted Outcomes in COPD Patients Newly Initiated on TRIXEO AEROSPHERE in Real worlD
- Conditions
- Chronic Obstructive Pulmonary Disease (COPD)
- Interventions
- First Posted Date
- 2024-04-16
- Last Posted Date
- 2025-04-15
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 250
- Registration Number
- NCT06368427
- Locations
- 🇷🇴
Research Site, Timisoara, Romania
Assessment Of Dose-Dependent Immunomodulatory Effect Of Alveofact With or Without Steroisd In Neonatal RDS
- Conditions
- Neutrophil Extracellular Trap FormationInflammatory ResponsePreterm BirthNeonatal Respiratory Distress SyndromePremature Lungs
- Interventions
- First Posted Date
- 2024-04-16
- Last Posted Date
- 2024-04-16
- Lead Sponsor
- Ain Shams University
- Target Recruit Count
- 60
- Registration Number
- NCT06367881
- Locations
- 🇪🇬
Egypt Neonatal Intensive Care Units (NICUs), Ain Shams University Cairo, Abbasia, Egypt, 11517, Cairo, Egypt
Molecular Signatures Associated With Response to ICS Treatment in Patients With COPD Stratified by Eosinophil Levels
- First Posted Date
- 2024-03-28
- Last Posted Date
- 2025-03-12
- Lead Sponsor
- Maria Joyera Rodríguez
- Target Recruit Count
- 135
- Registration Number
- NCT06334575
- Locations
- 🇩🇪
Philips University of Marburg, Marburg, Germany
🇳🇱Academisch Ziekenhuis Groningen, Groningen, Netherlands
🇪🇸Clínic Barcelona, Barcelona, Spain
A Study to Determine the Effect Food Has on TAK-721 (Budesonide Oral Suspension) in the Body of Healthy Adults
- First Posted Date
- 2024-02-20
- Last Posted Date
- 2024-12-02
- Lead Sponsor
- Takeda
- Target Recruit Count
- 20
- Registration Number
- NCT06268301
- Locations
- 🇺🇸
Celerion, Lincoln, Nebraska, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.